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Adherence in the Treatment of Patients With Extensively
Drug-Resistant Tuberculosis and HIV in South Africa:
A Prospective Cohort Study
Max R. O’Donnell, MD, MPH,*†‡ Allison Wolf, MPH,* Lise Werner, MSc,‡
C. Robert Horsburgh, MD, MUS,§ and Nesri Padayatchi, MBChB, MSc‡k
Objective: Extensively drug-resistant tuberculosis (XDR-TB)/HIV
coinfection is difficult to treat with frequent adverse drug reactions and
associated with high mortality. Adherence to antiretroviral therapy
(ARV) and second-line TB medications may reduce mortality, prevent
amplification of drug resistance, and improve outcomes.
Methods: Prospective cohort study of XDR-TB patients on
treatment in KwaZulu-Natal, South Africa. Adherence to ARV
and TB medications was assessed separately at baseline and
monthly. Knowledge, attitudes, and beliefs were assessed at
baseline. Optimal adherence was defined as self-report of taking
all pills in the previous 7 days; missing any pills was defined as
suboptimal adherence. Primary outcome was optimal adherence 6
months after initiation of XDR-TB treatment to TB medications,
ARV, and both (“dual adherence”).
Results: One hundred four XDR-TB patients (79.8% HIV co-
infected, 84.3% on ARV at enrollment) were enrolled and followed
monthly (median 8 visits; interquartile range: 4–12). Six-month opti-
mal adherence was higher for ARV (88.2%) than TB medications
(67.7%) (P , 0.001). Low educational attainment, male gender, and
year of enrollment were independently associated with dual subop-
timal adherence. At baseline, participants indicated that XDR-TB
was curable (76.0%), HIV and TB were linked (81.7%), and ARV
improves TB outcomes (72.1%). Baseline knowledge, attitudes, and
beliefs did not predict subsequent adherence.
Conclusions: Medication adherence was significantly higher for
ARV than for TB medications in this cohort. Short-course treatment
regimens for drug-resistant TB with lower pill burden may increase
adherence and improve outcomes in XDR-TB/HIV. Programmatic
support for dual adherence is critical in the treatment of drug-
resistant TB and HIV.
Key Words: extensively drug-resistant tuberculosis, HIV/AIDS,
adherence, knowledge, attitudes and beliefs
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INTRODUCTION
Extensively drug-resistant tuberculosis (XDR-TB), the
most resistant form of tuberculosis (TB),1 is difficult to treat2
and is associated with substantial mortality3,4 and poor treat-
ment outcomes.5,6 Globally, the majority of reported cases of
XDR-TB are from South Africa.7,8 XDR-TB in South Africa
is characterized by a high percentage of HIV coinfection,
early mortality, and poor 24-month treatment outcomes.9–11
XDR-TB–HIV treatment involves complex medication regi-
mens with potential drug interactions and adverse drug reac-
tions.12 A recent prospective study of XDR-TB treatment in
South Africa described ongoing community spread of drug-
resistant TB strains and low rates of TB culture conversion
with frequent reversion.13 However, medication adherence
was not measured in this study.
Medication adherence is critical for both HIV and TB
outcomes, and suboptimal adherence mediates the develop-
ment of antimycobacterial and antiretroviral drug resistance
on treatment.14–16 Early studies have shown that approxi-
mately 95% adherence to antiretroviral therapy (ARV) is
needed to ensure HIV viral suppression.17,18 Later studies
using more potent and durable regimens have demonstrated
viral suppression with lower adherence.19,20 Clinical trials of
drug-susceptible TB treatment have shown that 95% of pa-
tients are capable of successful outcome with direct observa-
tion and support by study personnel.21 Under operational
conditions many patients default their TB treatment and suc-
cessful outcomes range from 55% to 95%.22,23 Medication
adherence in patients with drug-resistant TB and HIV is
understudied; to our knowledge, there are no published re-
ports in this group.
Patient adherence in HIV and TB treatment has been
recently reviewed.24,25 A “gold standard” for measuring
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medication adherence in either field is controversial and each
method has strengths and weaknesses.26 Patient-reported
recall is widely used in measuring HIV medication adherence
and has been shown to correlate with ARV pill count and
HIV viral load suppression.27 There are no validated instru-
ments to measure medication adherence in the treatment of
drug-resistant TB.
Adherence to both TB medications and ARV may be
affected by patient’s knowledge, attitudes, and beliefs
(KAB).28,29 Factors associated with KAB include poverty,
gender, education, perceived stigma around HIV or TB or
both, and other social, structural, and cultural factors.24,30–32
To understand factors associated with treatment outcomes
and survival in XDR-TB–HIV, we initiated a prospective
study of XDR-TB treatment (PROX Study) in KwaZulu-
Natal, South Africa. Our primary aim was to measure adher-
ence to ARV and TB medication and understand factors
associated with suboptimal adherence. A secondary aim
was to understand the effect of baseline KAB on early
self-reported adherence to TB treatment and ARV. Our
hypothesis was that baseline knowledge of the connection
between HIV and TB would be associated with improved
adherence to ARV and second-line TB treatment among
XDR-TB- and HIV-coinfected patients.33
METHODS
We prospectively enrolled consecutive patients with
culture-confirmed XDR-TB admitted for initiation of XDR-
TB treatment at a public TB specialist hospital in KwaZulu-
Natal, South Africa, from August 2009 through July 2011.
Patients were eligible for enrollment if they were 18 years or
older, diagnosed with active TB disease according to national
TB program guidelines, had culture-proven XDR-TB accord-
ing to a standard case definition, had not been previously
treated for XDR-TB, agreed to start treatment for XDR-TB,
and had capacity to give informed consent in either English or
isiZulu. Prisoners and patients previously treated for XDR-
TB were excluded. Patients received usual care for XDR-TB
(ie, individualized therapy based on drug susceptibility
pattern), HIV, and other diseases.
All participants gave written informed consent, and the
study protocol was approved by the ethical review commit-
tees of the University of KwaZulu-Natal and the Albert
Einstein College of Medicine.
Adherence was measured by separate 7-day recall for
ARV and second-line TB medications (“TB medications”) in
a questionnaire administered by study staff fluent in both
English and isiZulu at study intake and monthly, as previously
described34 (see Supplemental Text Box 1, Supplemental
Digital Content, http://links.lww.com/QAI/A536). For the
purposes of analysis, a cumulative 6-month adherence variable
(for TB and separately for ARV) was used, which included
responses given at baseline and at the monthly visits.18 Partic-
ipants were considered “optimally adherent” at each monthly
visit only if they stated that they had taken all of their doses and
missed none. If participants stated that they had not taken all or
missed some of the medications, they were considered “sub-
optimally adherent” for that class of medications (either ARV
or TB medication).14 For the purposes of analysis, a cumulative
6-month adherence variable was used for TB and separately for
ARV, which included responses given at baseline and at the 1-
to 6-month time points. The participants were considered opti-
mally adherent for the cumulative 6-month adherence for
ARV, XDR-TB medications, or both ARV and XDR-TB med-
ications (“dual adherence”) only if they were optimally adher-
ent for all time points.
KAB around TB and HIV were assessed through
a questionnaire administered at baseline before XDR-TB
treatment initiation. A study staff person fluent in English
and isiZulu administered the KAB questionnaire, adherence
questions, and recorded clinical and demographic data.
Hospitalized patients were cared for in open wards by
nursing staff with approximately 20 patients per health care
FIGURE 1. Percentage of patients
with BL and monthly cumulative
optimal treatment adherence to
ARV, TB medications. Numbers re-
porting adherence data for ARV, TB
medications (TB), or both (dual) at
each monthly visit in the table
below. Data censored at time of
death (N = 19/104). BL, baseline.
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worker. Although all medications are given to patients, the
ward nurse does not directly observe them taking their
medications. In addition, patients may refuse a specific pill
or injection. As outpatients, patients are enrolled in the public,
provincial directly observed therapy (DOTS) program that
relies on a community or household DOTS supporter to
provide patient support and attest through signature that the
medications are being taken correctly and on schedule.
Physicians check DOTS support cards at monthly visits.
During the second and third years of the study, a patient
support and education initiative was started to enhance
adherence and improve patient care. This consisted of 2 staff
members meeting with small groups of XDR-TB patients on
a weekly basis. The purpose was to develop patient peer
support and to encourage adherence and provide patient-
oriented information around topics associated with drug-
resistant TB and HIV.
Descriptive statistics were calculated using standard
methods. Associations were tested with Fisher exact test;
paired values were tested using McNemar test. To identify
factors associated with incomplete adherence to ARV or TB
medications, we first identified factors in bivariate analysis and
then constructed multiple logistic regression models including
variables that were statistically significant and/or associated
with .10% change in effect measure. Interaction between
terms was assessed for significant change of the risk estimate.
Test for trend was performed using Cochran–Armitage test.
Statistical analysis was performed using SAS Version 9.3
(SAS Institute, Cary, NC).
RESULTS
Participant Characteristics
During the study period, 110 consecutive patients aged
18 years or older with culture-confirmed XDR-TB and
without previous treatment for XDR-TB presented to the
study site. Of these, 5 patients either refused to participate or
lacked capacity to consent. One XDR-TB patient was
a prisoner and therefore ineligible to enroll by study protocol.
The remaining 104 XDR-TB patients were eligible, gave
written informed consent, and were prospectively enrolled in
the study within 2 weeks of initiation of XDR-TB treatment.
The majority of participants were female (52%), young
(median age: 35 years, range: 18–60 years), and HIV coin-
fected (79.8%). Among HIV-coinfected patients, 84.3% were
on ARV and median CD4 count at baseline was 267 cells per
cubic millimeter [interquartile range (IQR): 135–452 cells/
mm3]. Of these patients, 70 (85%) of 82 were on ARV at
the time of admission and an additional 9% (7/82) were
started subsequently (median time to ARV initiation 136
days). These patients reported relatively high levels of edu-
cational attainment (32% completed secondary) and monthly
income (median $296; IQR: $185–$588). The majority of
patients had been previously treated for drug-sensitive TB
(92.3%) and for multi-drug-resistant TB (57.7%) (Table 1).
XDR-TB treatment was based on drug susceptibility
testing to 6 antimycobacterial drugs (isoniazid, rifampicin,
ofloxacin, streptomycin, kanamycin, and ethambutol) and
consisted of on average 7 (range: 4–9) antimycobacterial
drugs. The majority of patients were on an initial TB treat-
ment regimen, including capreomycin, moxifloxacin, para-
amino salicylic acid, ethionamide (98.1%), terizidone, and
pyrazinamide (96.2%). XDR-TB patients were started on
a median 7 (range: 4–9) TB medications and 3 ARV (range:
3–5). Patients were treated with ARV regimens that included
nonnucleotide reverse transcriptase inhibitors (efavirenz, N =
68; neviripine, N = 3; not recorded, N = 6) and nucleotide
reverse transcriptase inhibitors. During the study period, 2
patients were changed to protease inhibitor-containing regi-
mens after clinically failing treatment. Overall median time of
TABLE 1. Demographic Characteristics of XDR-TB Patients
Initiated on XDR-TB Therapy During Study Period


















CD4 T-cell count‡ (cells/mm3)
Known 74 (89)
Unknown 9 (11)
Median CD4 count (IQR) 267 (135–452)
HIV positive on ARV§
Yes 77 (92.7)
No 6 (7.3)
TB medications, n (range) 7 (4–9)







History of being a health care worker
Yes 5 (4.8)
No 99 (95.2)
*Calculated from South African Rand at exchange rates from July 2011. Income
data missing for 8 patients.
†HIV infected includes known HIV infected on admission (82) and diagnosed as
HIV infected subsequently (1).
‡Among HIV-infected patients; patients with known CD4 T-cell counts who had at
least 1 count during the study period.
§On ARV includes ARV on admission (70) and ARV initiated subsequently (7).
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follow-up for all XDR-TB patients on treatment was 9
months (IQR: 2–19 months). Median inpatient time was
144 days (IQR: 77–189 days).
Adherence Data
We obtained self-reported TB medication adherence data
for all 104 XDR-TB patients and adherence data for 68 (88%)
of 77 patients on ARV. On average, each patient had 8 monthly
visits (IQR: 3–14) during which adherence to ARV and TB
medications was assessed by self-reported 7-day recall. Among
all XDR-TB patients on treatment, 67.3% reported optimal 6-
month adherence to TB medications, whereas among XDR-TB-
and HIV-coinfected patients on ARV, 88.2% reported optimal
adherence to ARV (Table 2). Among XDR-TB- and HIV-
coinfected patients on both XDR-TB medications and ARV,
optimal 6-month adherence to ARV was 88.2% and optimal
6-month adherence to TB medications was 67.7% (P, 0.001).
In total, 64.3% reported optimal 6-month adherence to both TB
medications and ARV (“dual adherence”). Optimal adherence
to ARV was significantly associated with optimal adherence to
TB medications [odds ratio (OR): 21.0; 95% confidence inter-
val (CI): 2.38 to 184.89, P = 0.006]. The largest subset (15/25)
of patients nonadherent to either ARV or second-line TB med-
ications reported optimal adherence to ARV but not to TB
medications (Table 3).
On longitudinal analysis, initially 95% of patients
reported optimal adherence to ARV and 71% reported
optimal adherence to TB medications, and among patients
on ARV and TB medications, 67% reported optimal adher-
ence to both. At month 4, cumulative optimal adherence to
ART (87%), TB medications (67%), and both (64%) were
lower and continued to slowly decline through the first 12
months of treatment (Fig. 1). However, there was not a signif-
icant decline in adherence after the end of the intensive phase,
which included nurse-administered injectable agents for the
majority of patients (92%).
Among the patients who reported suboptimal adherence
to TB medications, 13 (59%) of 22 reported they took “most”
or “missed few” of their medications, 7 (32%) of 22 reported
taking few or often missing their TB medications, and 2 (9%)
of 22 reported always missing or never taking their TB med-
ications. Among patients on ARV who reported suboptimal
adherence, 7 (88%) of 8 reported that they took “most” or
“missed few” of their ARV and 1 (12%) of 8 reported always
missing or never taking his ARV. Among XDR-TB–HIV pa-
tients with at least 6 consecutive monthly visits, 57.6% report 6
visits with optimal ARV adherence as compared with 37.5%
reporting optimal TB medication adherence on 6 consecutive
visits. Number of monthly study visits with self-reported opti-
mal adherence to TB medications was correlated with TB cul-
ture conversion over the course of XDR-TB treatment. TB
culture conversion was defined as 2 consecutive negative cul-
tures taken $30 days apart (see Figure S1, Supplemental
Digital Content, http://links.lww.com/QAI/A536).
XDR-TB- and HIV-coinfected patients were less adher-
ent to TB medications (65.1%) than HIV-negative XDR-TB
patients (76.2%) (P = 0.33). For XDR-TB patients not on
ARV at baseline, optimal TB medication adherence was
63.6%, not significantly different compared with TB medica-
tion adherence in XDR-TB patients on ARV (65.7%) (P =
1.00). Patients seemed to be less adherent to their overall
XDR-TB medication regimens if they included cycloserine
(33.3%), but this difference was not statistically significant
(P = 0.09) (see Figure S2, Supplemental Digital Content,
http://links.lww.com/QAI/A536).
On multivariate analysis, higher educational attainment
was associated with optimal dual adherence at 6 months (OR:
5.39; 95% CI: 1.03 to 28.25). Women were more likely to
report being optimally adherent (OR: 4.68; 95% CI: 1.11 to
19.68) as were younger patients, although this association
was not statistically significant (OR: 2.95; 95% CI: 0.65 to
13.42). In addition, there was significantly lower dual optimal
adherence among patients who enrolled earlier, in 2009,
compared with patients who enrolled later, in 2011 (test for
trend, P , 0.001). The variable “adverse drug reaction” was
not included in the multivariate analysis because including the
variable did not change estimates of effect and many partic-
ipants had missing data (N = 20) (Table 4).
In the baseline KAB questionnaire, participants were
optimistic regarding adhering to XDR-TB treatment for .2
years (80.8%), being cured of XDR-TB (76.0%), and success-
fully completing treatment (96.2%). Participants identified
linkages between TB and HIV (81.7%), ARV and XDR-TB
treatment (72.1%), and modes of TB transmission (97.1%).
About half of all patients (48.1%) incorrectly identified sharing
a cup as a possible mode of transmission. Answers to these
KAB questions were not significantly associated with
increased percentages of optimal adherence to TB medications
or to both TB medications and ARV at 6 months (Table 5).
TABLE 2. Cumulative 6-Month Optimal Adherence to ARV
and TB Medications in All XDR-TB Patients (N = 104)
TB Medication Adherence ARV Adherence* Dual Adherent†
70/104 (67.3) 60/68 (88.2) 45/68 (66.2)
*Seventy-five patients reported being on ARV at 6 months; 68 provided adherence
data.
†Calculated among HIV-infected individuals on ARV with adherence data. Count
includes individuals who are dual adherent to both ARV and TB medications. One
patient provided ARV adherence data but not TB adherence data.
TABLE 3. Cumulative 6-Month Optimal Adherence in
XDR-TB- and HIV-coinfected Patients on Both ARV and TB








Optimal adherence 45 1
Suboptimal adherence 15 7
Sometimes nonadherent 9 (60.0) 4 (57.1)
Often nonadherent 4 (26.7) 3 (42.9)
Always nonadherent 2 (13.3) 0
XDR-TB medication adherence 46/68 (67.7%)
ARV adherence 60/68 (88.2%) P , 0.001
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DISCUSSION
To our knowledge, this is the first prospective study of
adherence in the integrated treatment of drug-resistant TB and
HIV. Our main finding is that patients being treated for XDR-
TB and HIV coinfection are significantly more likely to report
complete adherence to ARV compared with TB medications
through the first 6 months of their XDR-TB treatment. It is
probable that these self-reported adherence figures are an
overestimate because patients may be hesitant to report the
extent of their nonadherence to study staff.35,36 In our cohort,
KAB including knowledge of the relationship between TB
and HIV, attitudes around XDR-TB and HIV stigma, and
beliefs regarding adherence did not predict subsequent self-
reported adherence at 6 months.
Adherence in the treatment of drug-resistant TB–HIV is
critically important because adherence mediates treatment
outcomes, the development of drug resistance on treatment,
the infectivity of the patients on treatment, and is therefore
associated with transmission of TB infection in the commu-
nity. Improved adherence to ARV is associated with
improved survival in XDR-TB–HIV patients.10 However,
ARV does not seem to be associated with improved rates of
TB culture conversion in drug-susceptible or drug-resistant
TB.5,10,37 Therefore, if XDR-TB patients are adherent to
ARV but poorly adherent to TB medications, the concern is
that they will survive to spread drug-resistant TB strains in the
hospital and in the community and be more likely to develop
amplification of drug resistance on treatment.
Risk factors for incomplete adherence at 6 months
included male gender and low educational attainment, which is
consistent with some, but not all, previous studies.30,35,38,39 Year
of admission was also associated with complete adherence,
which may be due to improved patient education after our patient
support intervention, differential reporting bias, or other fac-
tors.33,40 We have identified risk groups (ie, men and lower
educated patients) who may be amenable to specific interven-
tions to improve adherence. In addition, the finding that the
majority of TB suboptimal adherent patients do report optimal
ARV adherence is helpful. It suggests that these patients are not
intrinsically nonadherent and that with enhanced patient support,
education, and most importantly more tolerable TB drug regi-
mens, it may be possible to improve adherence for these patients.
The 6-month adherence data predominantly represent
in-hospital adherence because patients were hospitalized for
TABLE 4. Univariate and Multivariate Analysis of Factors Associated With Optimal Adherence to TB Medications, ARV, and Both
(Dual) at 6 Months
TB Medication Adherence
N = 104 (%)*
ARV Adherence
N = 70 (%)†
Dual Adherence






Male 29/50 (58.0) 25/31 (80.7) 16/29 (55.2) 1.00 (ref) 1.00 (ref)
Female 41/54 (75.9) 35/39 (89.7) 29/39 (74.4) 2.72 (0.99 to 7.44) 4.68 (1.11 to 19.68)
Age (yr)
,35 35/49 (71.4) 24/28 (85.7) 18/28 (64.3) 1.00 (ref) 2.95 (0.65 to 13.42)
$35 35/55 (63.6) 36/42 (85.7) 27/40 (67.5) 1.00 (0.37 to 2.71) 1.00 (ref)
Completed primary
school
No 8/21 (38.1) 10/16 (62.5) 5/16 (31.3) 1.00 (ref) 1.00 (ref)
Yes 60/81 (74.1) 48/52 (92.3) 38/52 (73.1) 5.97 (1.76 to 20.26) 5.39 (1.03 to 28.25)
Previous XDR-TB
History
No 24/44 (54.6) 24/29 (82.8) 16/29 (55.2) 1.00 (ref) 1.00 (ref)
Yes 46/60 (76.7) 36/41 (87.8) 29/41 (70.7) 1.96 (0.73 to 5.31) 0.78 (0.19 to 3.15)
Income (ZAR)
,R2010 32/48 (66.7) 31/38 (81.6) 23/38 (60.5) 1.00 (ref) 1.00 (ref)
$R2010 32/48 (66.7) 27/30 (90.0) 20/30 (66.7) 1.30 (0.48 to 3.54) 1.96 (0.44 to 8.66)
Year enrolled
2011 38/42 (90.5) 27/30 (90.0) 26/30 (86.7) 1.00 (ref) 1.00 (ref)
2010 28/42 (66.7) 26/29 (89.7) 18/29 (62.1) 0.25 (0.07 to 0.92) 0.41 (0.09 to 1.78)
2009 4/20 (20.0) 7/11 (63.6) 1/11 (9.1) 0.02 (0.00 to 0.15) 0.01 (0.00 to 0.13)
Adverse events on
treatment§
No 13/24 (54.2) 11/15 (73.3) 7/15 (46.7) 1.00 (ref)
Yes 30/51 (58.8) 28/33 (84.9) 17/33 (51.5) 1.21 (0.36 to 4.12)
ZAR, South African Rand.
*Calculation based on individuals with adherence data (N = 104) within the first 6 months of follow-up.
†Calculation based on individuals with ARV adherence data (N = 70) within the first 6 months of follow-up.
‡Analysis includes patients with ARV and TB adherence data (N = 68).
§Within the first 6 months of follow-up.
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TABLE 5. Baseline KAB With Overall Stratified by Percent Adherent to TB Medications in all XDR-TB Patients (n = 104) and Both TB
Medications and ARV Adherent (“Dual”) in XDR-TB–HIV Patients (N = 68)
KAB Question Overall, N (%) TB Medication Adherent, n/N (%) Dual Adherent, n/N (%)
Is XDR-TB curable? No 7 (6.7) 4/7 (57.1) 2/5 (40.0)
Yes 79 (76.0) 55/79 (69.6) 38/56 (67.9)
Don’t know 18 (17.3) 11/18 (61.1) 5/7 (71.4)
P 0.66 0.43
Is XDR-TB treatment .2 yrs? No 4 (3.8) 1/4 (25.0) 1/1 (100.0)
Yes 84 (80.8) 59/84 (70.2) 40/60 (66.7)
Don’t know 16 (15.4) 10/16 (62.5) 4/7 (57.1)
P 0.15 0.79
Not taking medications every day will likely make my
XDR-TB worse?
No 1 (1.0) 0/1 (0.0) 0/1 (0.0)
Yes 95 (91.3) 64/95 (67.4) 44/65 (6.7)
Don’t know 8 (7.7) 6/8 (75.0) 1/2 (50.0)
P 0.40 0.41
I think I will complete XDR-TB treatment successfully? No 0 (0.0) — —
Yes 100 (96.2) 67/100 (67.0) 44/66 (66.7)
Don’t know 4 (3.8) 3/4 (75.0) 1/2 (50.0)
P 1.00 1.00
Is there a link between TB and HIV? No 7 (6.7) 4/7 (57.1) 0/1 (0.0)
Yes 85 (81.7) 58/85 (68.2) 40/58 (69.0)
Don’t know 12 (11.5) 8/12 (66.7) 5/9 (55.6)
P 0.85 0.32
ARV for my HIV helps to fight XDR-TB? No 5 (4.8) 3/5 (60.0) 2/4 (50.0)
Yes 75 (72.1) 55/75 (73.3) 38/53 (71.7)
Don’t know 24 (23.1) 12/24 (50.0) 5/11 (45.5)
P 0.10 0.17
XDR-TB transmitted by air when XDR-TB patient
coughs?
No 1 (1.0) 1/1 (100.0) 1/1 (100.0)
Yes 101 (97.1) 68/101 (67.3) 44/66 (66.7)
Don’t know 2 (1.9) 1/2 (50.0) 0/1 (0.0)
P 1.00 0.57
XDR-TB transmitted by sharing a cup? No 41 (39.4) 27/41 (65.9) 17/27 (63.0)
Yes 50 (48.1) 37/50 (74.0) 25/35 (71.4)
Don’t know 13 (12.5) 6/13 (46.2) 3/6 (50.0)
P 0.17 0.51
Enough information about XDR-TB? No 63 (60.6) 44/63 (69.8) 27/39 (69.2)
Yes 34 (32.7) 20/34 (58.8) 15/25 (60.0)
Don’t know 7 (6.7) 6/7 (85.7) 3/4 (75.0)
P 0.37 0.77
XDR-TB patients treated respectfully? No 7 (7.1) 6/7 (85.7) 3/3 (100.0)
Yes 86 (86.9) 56/86 (65.1) 36/56 (64.3)
Don’t know 6 (6.1) 4/6 (66.7) 3/5 (60.0)
Missing 5
P 0.58 0.78
Told family and friends about XDR-TB? No 10 (9.6) 6/10 (60.0) 3/6 (50.0)
Yes 93 (89.4) 63/93 (67.7) 41/61 (67.2)
Don’t know 1 (1.0) 1/1 (100.0) 1/1 (100.0)
P 0.82 0.61
Family/friends treat differently with XDR-TB? No 87 (85.3) 60/87 (69.0) 41/59 (69.5)
Yes 9 (8.8) 4/9 (44.4) 1/5 (20.0)
Don’t know 6 (5.9) 5/6 (83.3) 2/3 (66.7)
Missing 2
P 0.26 0.11
Should treat XDR-TB at patient’s community level? No 1 (1.0) 0/1 (0.0) 0/1 (0.0)
Yes 99 (95.2) 67/99 (67.7) 44/65 (67.7)
Don’t know 4 (3.8) 3/4 (75.0) 1/2 (50.0)
P 0.53 0.41
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a median of 4.7 months. Given high patient-to-nurse ratios,
therapy in hospital is seldom directly observed. Self-reported
7-day adherence to ARV and XDR-TB medications
decreased significantly during the first 12 months on treat-
ment and may represent in part the transition from inpatient to
outpatient care. On discharge from hospital to outpatient care,
patients are enrolled in the local DOTS program. This
program is underresourced and relies on family members
and friends to provide patient support. It is likely that the
reported limitations of DOTS for drug-susceptible TB lead to
even less effective adherence in the treatment of drug-
resistant TB–HIV.
A major limitation of our study is the reliance on self-
reported 7-day recall for adherence. Self-reported 7-day recall
was the only means of measuring adherence in this study.
Seven-day recall has been used extensively in ARV adher-
ence studies where it has been shown to correlate with
percentage of patients with undetectable HIV RNA viral
load.31,36 Seven-day recall has not been validated as a measure
of adherence in the treatment of drug-resistant TB.14,34 Self-
reported adherence based on recall may lead to overestima-
tion or less likely underestimation of actual adherence due to
reporting or recall bias. It is unlikely that there was differen-
tial error with respect to ARV and TB medications and there-
fore it is likely that XDR-TB patients in this cohort do have
lower rates of adherence to TB medications than ARV. Other
limitations include relatively short duration of follow-up,
which limits our ability to comment on implications for treat-
ment outcome or mortality. Another limitation is that we lack
precise data on how changes in medications or adverse drug
reactions during treatment affect adherence.
The potential implication of our main finding is that
XDR-TB–HIV patients in KwaZulu-Natal, South Africa, may
have reduced mortality with higher adherence to ARV and yet
have decreased TB culture conversion due to poor adherence
to XDR-TB medications. Incomplete TB adherence with pro-
longed survival may also result prolonged transmission of
infectious strains in the community and in amplification of
TB drug resistance on treatment, which is consistent with the
epidemiology of drug-resistant TB in KwaZulu-Natal prov-
ince.41 To address these findings, shorter duration regimens
for treatment of drug-resistant TB are needed. As such TB
regimens are introduced, it will be important to introduce
programs for patient and adherence support, including ongo-
ing monitoring and evaluation. Additional resources need to
be devoted to enhancing adherence for drug-resistant TB–
HIV within the context of TB–HIV control programs.
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